TTX-080 for Advanced Cancers
This study is testing a drug called TTX-080, alone or with other approved cancer treatments like pembrolizumab, cetuximab, or FOLFIRI, for people with advanced cancers. TTX-080 is a monoclonal antibody (a type of immune therapy) that blocks HLA-G, which may help the immune system fight cancer. The study aims to see how well TTX-080 works by measuring tumor shrinkage (objective response rate). Currently, only people with advanced colorectal cancer can join. You might be eligible if you are 18 or older, have measurable cancer, and a good performance status. The study plans to enroll 240 participants.
- Study design
- This is a Phase 1, open-label (meaning you and your doctors will know what treatment you are receiving) study. It is testing different doses of TTX-080 alone and in combination with other drugs.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure how well the treatment works for up to 48 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
At a glance
Conditions
Where it's being run
41 sites across 26 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- 1. To determine the anti-tumor activity of TTX-080 by objective response rate [complete response + partial response) for each tumor arm per RECIST 1.1Up to 48 months